William Rieflin joins Anacor's board
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals has elected William Rieflin to its board of directors; he will also serve as chair of the audit committee. Mr Rieflin, who has more than 20 years' industry experience, is chief executive officer of NGM Biopharmaceuticals. He was previously president of XenoPort and currently serves on their board of directors.